Medlab Clinical Ltd
ASX:MDC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medlab Clinical Ltd
Selling, General & Administrative
Medlab Clinical Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medlab Clinical Ltd
ASX:MDC
|
Selling, General & Administrative
-AU$2.1m
|
CAGR 3-Years
41%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Selling, General & Administrative
-$50.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
|
CSL Ltd
ASX:CSL
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-12%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Selling, General & Administrative
-AU$3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Selling, General & Administrative
-AU$192.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Selling, General & Administrative
-AU$5.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-11%
|
|
Medlab Clinical Ltd
Glance View
Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.
See Also
What is Medlab Clinical Ltd's Selling, General & Administrative?
Selling, General & Administrative
-2.1m
AUD
Based on the financial report for Jun 30, 2024, Medlab Clinical Ltd's Selling, General & Administrative amounts to -2.1m AUD.
What is Medlab Clinical Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
28%
Over the last year, the Selling, General & Administrative growth was 73%. The average annual Selling, General & Administrative growth rates for Medlab Clinical Ltd have been 41% over the past three years , 28% over the past five years .
